{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T07:19:09Z","timestamp":1774855149228,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.biopha.2025.118108","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T06:46:51Z","timestamp":1745822811000},"page":"118108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Enhanced tumor suppressive effect of a new HDAC inhibitor in bladder cancer in vitro and in vivo"],"prefix":"10.1016","volume":"187","author":[{"given":"Cheng-Huang","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shou-Chieh","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Xuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun-Wei","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Say-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Yang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4715-3800","authenticated-orcid":false,"given":"Yi-Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118108_bib1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: A systematic review of risk factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.biopha.2025.118108_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2025.118108_bib3","article-title":"Bladder cancer: current challenges and future directions","volume":"57","author":"Dobruch","year":"2021","journal-title":"Med. (Kaunas. )"},{"key":"10.1016\/j.biopha.2025.118108_bib4","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1038\/551S34a","article-title":"Unlocking bladder cancer","volume":"551","author":"Berdik","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118108_bib5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.biopha.2025.118108_bib6","first-page":"507","article-title":"Bladder cancer: Diagnosis and treatment","volume":"96","author":"DeGeorge","year":"2017","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.biopha.2025.118108_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101312","article-title":"HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases","volume":"16","author":"Shanmugam","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.biopha.2025.118108_bib8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3802\/jgo.2008.19.3.185","article-title":"Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues","volume":"19","author":"Jin","year":"2008","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2025.118108_bib9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ijc.11403","article-title":"Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha","volume":"107","author":"Kawai","year":"2003","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.biopha.2025.118108_bib10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2164-7-90","article-title":"Differential expression of selected histone modifier genes in human solid cancers","volume":"7","author":"Ozdag","year":"2006","journal-title":"BMC Genom."},{"key":"10.1016\/j.biopha.2025.118108_bib11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nbt1272","article-title":"Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug","volume":"25","author":"Marks","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2025.118108_bib12","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2025.118108_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118108_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010077","article-title":"HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1\/JAK1\/FGL1 axis in lung adenocarcinoma","volume":"12","author":"Xu","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118108_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116257","article-title":"HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancer","volume":"225","author":"Jenke","year":"2024","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.biopha.2025.118108_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e41589","article-title":"The potential synergistic effect of combining doxorubicin with vorinostat in urothelial carcinoma therapy","volume":"11","author":"Shen","year":"2025","journal-title":"Heliyon"},{"key":"10.1016\/j.biopha.2025.118108_bib17","article-title":"Vorinostat enhances the therapeutic potential of Erlotinib via MAPK in lung cancer cells","volume":"30","author":"Alqosaibi","year":"2022","journal-title":"Cancer Treat. Res Commun."},{"key":"10.1016\/j.biopha.2025.118108_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.109876","article-title":"Synthesis, in vitro and structural aspects of cap substituted Suberoylanilide hydroxamic acid analogs as potential inducers of apoptosis in Glioblastoma cancer cells via HDAC \/microRNA regulation","volume":"357","author":"Mekala","year":"2022","journal-title":"Chem. Biol. Inter."},{"key":"10.1016\/j.biopha.2025.118108_bib19","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.stem.2022.09.009","article-title":"Glioblastoma stem cell-specific histamine secretion drives pro-angiogenic tumor microenvironment remodeling","volume":"29","author":"Chen","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.biopha.2025.118108_bib20","first-page":"2114","article-title":"Analysis of the effects of cyproheptadine on bladder cancer through big data","volume":"10","author":"Chang","year":"2020","journal-title":"Am. J. Cancer Res"},{"key":"10.1016\/j.biopha.2025.118108_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2015.09.018","article-title":"Cyproheptadine exhibits antitumor activity in urothelial carcinoma cells by targeting GSK3beta to suppress mTOR and beta-catenin signaling pathways","volume":"370","author":"Hsieh","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2025.118108_bib22","first-page":"851","article-title":"Improved HDAC inhibition, stronger cytotoxic effect and higher selectivity against leukemias and lymphomas of novel, tricyclic vorinostat analogues","volume":"14","author":"Bieszczad","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"10.1016\/j.biopha.2025.118108_bib23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.biopha.2025.118108_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218382","article-title":"Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells","volume":"14","author":"Eto","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118108_bib25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2710.2009.01095.x","article-title":"Solubilization of vorinostat by cyclodextrins","volume":"35","author":"Cai","year":"2010","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2025.118108_bib26","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1038\/jid.2012.125","article-title":"Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling","volume":"132","author":"Al-Yacoub","year":"2012","journal-title":"J. Invest Dermatol."},{"key":"10.1016\/j.biopha.2025.118108_bib27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: Achieving the full therapeutic potential of HDACi","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2025.118108_bib28","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s10495-016-1278-6","article-title":"Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the expression of microRNAs in hepatocellular carcinoma","volume":"21","author":"Srinivas","year":"2016","journal-title":"Apoptosis"},{"key":"10.1016\/j.biopha.2025.118108_bib29","doi-asserted-by":"crossref","first-page":"77254","DOI":"10.18632\/oncotarget.20460","article-title":"Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines","volume":"8","author":"Bernhart","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2025.118108_bib30","first-page":"1503","article-title":"Vorinostat induces G2\/M cell cycle arrest in breast cancer cells via upregulation of PTEN","volume":"27","author":"Alqosaibi","year":"2023","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.biopha.2025.118108_bib31","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood.V108.11.2260.2260","article-title":"The histone deacetylase inhibitor vorinostat (SAHA) induces apoptosis and cell cycle arrest in Hodgkin lymphoma (HL) cell lines by altering several survival signaling pathways and synergizes with doxorubicin, gemcitabine and bortezomib","volume":"108","author":"Georgakis","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118108_bib32","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.urolonc.2012.06.015","article-title":"Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers","volume":"31","author":"Niegisch","year":"2013","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.biopha.2025.118108_bib33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1472-6890-14-10","article-title":"Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer","volume":"14","author":"Poyet","year":"2014","journal-title":"BMC Clin. Pathol."},{"key":"10.1016\/j.biopha.2025.118108_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091327","article-title":"Selective inhibition of histone deacetylases 1\/2\/6 in combination with gemcitabine: A promising combination for pancreatic cancer therapy","volume":"11","author":"Laschanzky","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2025.118108_bib35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/1471-2164-11-257","article-title":"Core promoter structure and genomic context reflect histone 3 lysine 9 acetylation patterns","volume":"11","author":"Kratz","year":"2010","journal-title":"BMC Genom."},{"key":"10.1016\/j.biopha.2025.118108_bib36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jdermsci.2021.07.003","article-title":"H3K27Ac modification and gene expression in psoriasis","volume":"103","author":"Masalha","year":"2021","journal-title":"J. Dermatol. Sci."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T19:56:24Z","timestamp":1759002984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225003026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":36,"alternative-id":["S0753332225003026"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118108","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced tumor suppressive effect of a new HDAC inhibitor in bladder cancer in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118108"}}